Literature DB >> 10654105

The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies.

H Häfner1, W an der Heiden.   

Abstract

In schizophrenia most of the social consequences emerge in the prodromal phase of the illness and before treatment is initiated. Further course is determined by the level of social development at illness onset and by age- and sex-related illness behavior. Despite the sex difference in age at onset the disease process seems to be the same in both sexes, since social course in men and women converges in the long run. Although great variation in outcome between the patients is to be observed at each cross-section, the medium and long-term symptom-related course of schizophrenia shows a high degree of stability at the individual level.

Entities:  

Mesh:

Year:  1999        PMID: 10654105     DOI: 10.1007/pl00014180

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  30 in total

Review 1.  [Early recognition and intervention for schizophrenia].

Authors:  N Mossaheb; G Wiesegger; G P Amminger; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2006-01       Impact factor: 1.214

Review 2.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 3.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

4.  Evaluation of GPs diagnostic knowledge and treatment practice in detection and treatment of early schizophrenia: a French postal survey in Brittany.

Authors:  Mickael Le Galudec; Géraldine Cornily; Ronan Garlantézec; Florian Stéphan; Zarrin Alavi; Michel Walter
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-04-20       Impact factor: 4.328

5.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

6.  Effects of Endurance Training Combined With Cognitive Remediation on Everyday Functioning, Symptoms, and Cognition in Multiepisode Schizophrenia Patients.

Authors:  Berend Malchow; Katriona Keller; Alkomiet Hasan; Sebastian Dörfler; Thomas Schneider-Axmann; Ursula Hillmer-Vogel; William G Honer; Thomas G Schulze; Andree Niklas; Thomas Wobrock; Andrea Schmitt; Peter Falkai
Journal:  Schizophr Bull       Date:  2015-03-17       Impact factor: 9.306

7.  The Bipolar Prodrome Symptom Interview and Scale-Prospective (BPSS-P): description and validation in a psychiatric sample and healthy controls.

Authors:  Christoph U Correll; Doreen M Olvet; Andrea M Auther; Marta Hauser; Taishiro Kishimoto; Ricardo E Carrión; Stephanie Snyder; Barbara A Cornblatt
Journal:  Bipolar Disord       Date:  2014-05-08       Impact factor: 6.744

8.  Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome.

Authors:  Christoph U Correll; Julie B Penzner; Anne M Frederickson; Jessica J Richter; Andrea M Auther; Christopher W Smith; John M Kane; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2007-05-02       Impact factor: 9.306

9.  [The impact of the study design and the sampling procedure on the assessment of mental health services].

Authors:  R Kilian; C Roick; M C Angermeyer
Journal:  Nervenarzt       Date:  2003-06-26       Impact factor: 1.214

10.  The predictive validity of the Leonhardean classification of endogenous psychoses: a 21-33-year follow-up of a prospective study ("BUDAPEST 2000").

Authors:  Bertalan Petho; Judit Tolna; Gábor Tusnády; Márta Farkas; Györgyi Vizkeleti; András Vargha; Pál Czobor
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-02-25       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.